About Scp Cardiovasculaire De L'Est
Clinical Trials at Scp Cardiovasculaire De L'Est
During the past decade, Scp Cardiovasculaire De L'Est conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Scp Cardiovasculaire De L'Est
According to Clinical.Site data, the most researched conditions in "Scp Cardiovasculaire De L'Est" are
"Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Scp Cardiovasculaire De L'Est" in a lesser frequency.
Clinical Trials Intervention Types at Scp Cardiovasculaire De L'Est
Most popular intervention types in "Scp Cardiovasculaire De L'Est" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Scp Cardiovasculaire De L'Est
The vast majority of trials in "Scp Cardiovasculaire De L'Est" are
2 trials for "All" genders.
Clinical Trials Status at Scp Cardiovasculaire De L'Est
Currently, there are NaN active trials in "Scp Cardiovasculaire De L'Est".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Scp Cardiovasculaire De L'Est,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Scp Cardiovasculaire De L'Est, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".